Apollo's $20B DePuy Bid Resets Orthopedic Valuations—Stryker's Premium Just Became a Moat

Stryker's premium is structural, not sentimental. The company exited FY2025 with $25.1 billion in total revenue (up 11.2%), $9.5 billion of which came from the Orthopaedics segment (up 4.3%), and accelerated to 9.1% segment growth in Q2 2026 driven by Mako installations. With an enterprise value of $117.2 billion against $25.8 billion in trailing revenue, Stryker commands 4.54x EV/sales today and 5.84x on FY2025. Zimmer Biomet, Smith & Nephew, Globus Medical and the DePuy bid all cluster between 2.27x and 3.06x—evidence that public markets have stopped paying for orthopedic scale alone.

Stryker exited 2025 with more than 3,000 Mako robotic systems installed worldwide, up from over 2,000 at year-end 2024. Mako now powers more than 50% of global knee implant procedures and over 20% of global hip implant procedures; in the U.S., more than two-thirds of Stryker knee surgeries are Mako-assisted. The company is launching Mako RPS—a handheld robotic version aimed at ambulatory surgery centers—mid-2026, locking in the lowest-cost site of care where competitors are weakest.

The orthopedic market is roughly $50 billion for implants and instruments, with joint replacement alone at ~$24 billion in 2025 and projected to expand to ~$30 billion by 2030. Inside that, knee share is split Zimmer Biomet 33%, Stryker 30%, DePuy 16%, Smith & Nephew 11%; hip share runs Stryker 26%, Zimmer Biomet 25%, DePuy 20%, Smith & Nephew 8%. Stryker's hip leadership is the segment robots do not yet dominate—suggesting Mako RPS and hip software can extend the moat into the area where DePuy is still strongest.

Apollo's $20B bid does something worse than punish Johnson & Johnson shareholders for 14 years of DePuy underperformance: it forces the rest of the orthopedic value chain to re-rate around a permanent two-tier structure. Stryker sits in tier one, with the installed base, the robotic system, and the multiple to fund both. The other four—including Stryker's traditional peers—now trade at or near the level Apollo is willing to pay for DePuy, which is roughly the price of an LBO underwritten on 3.0x EV/sales and a heavy debt stack.

Upstream, the carve-out is bullish for contract manufacturers and bearish for raw-material suppliers chasing large-OEM share. Integer Holdings—the largest pure-play medical device contract manufacturer at $1.85B FY2025 revenue—sells hip and knee reamers, chisels and other surgical instruments into the orthopedic channel and has EV/sales of 3.05x, in line with the DePuy multiple. The bigger inflection is the May 14, 2026 closing of the Tecomet + Orchid Orthopedic Solutions merger, which combined two PE-backed contract manufacturers (Charlesbank Capital and Nordic Capital) into a 24-facility global platform estimated near $1 billion in revenue. With DePuy now capital-constrained under LBO leverage, and Smith & Nephew retrenching, the consolidated Tecomet is positioned to absorb outsourced instrument, implant-finishing and additive-manufacturing work that tier-two OEMs increasingly cannot justify doing in-house.

Downstream, the consequences hit the customer. ~7 million patients annually flow through DePuy Synthes channels; under Apollo ownership, the unit will likely accelerate product rationalization, cut trauma and extremities SKUs, and price-discount more aggressively in markets where it has lost share. Hospitals and ambulatory surgery centers—the fastest-growing site of care for orthopedic procedures—will get a tier-two OEM that behaves more like a competitor on price and less like the research arm of Johnson & Johnson. For ASCs, Stryker's mid-2026 Mako RPS launch is the counterweight: a handheld robotic system designed for outpatient settings, lowering the capital cost of going robotic and effectively locking ASCs into Stryker implants and consumables.

Short-term (days to quarters): the read-through to Zimmer Biomet is the most acute. With public orthopedic comps now anchored at 3.0x EV/sales and DePuy likely to be delisted through 2027, ZBH trades at parity with a leveraged LBO target and offers no premium for its 33% U.S. knee share. Smith & Nephew's Q2 2026 guidance cut and the lowered full-year outlook on 'soft' first-half sales reinforce that tier-two is getting bid down before any actual consolidation happens. Integer Holdings and Apollo's stock should re-rate on each incremental disclosure of outsourcing commitments from DePuy or SNN.

Long-term (1–3 years): the structural question is whether the tier-two cluster—DePuy private, ZBH public, SNN public, GMED public—consolidates around two surviving scaled players or remains a fragmented, cost-cut value trap. Apollo's playbook historically points to a 5–7 year hold with operational improvement and eventual strategic exit; the bull case for Stryker is that even one less competitive tier-two OEM (via DePuy/SNN/ZBH M&A) extends Mako's pricing power through 2030. The bear case is that PE-owned DePuy emerges leaner in 2028 with $5B+ of fresh Mako-like robotic capability funded by recapitalization—turning the two-tier structure into a knife fight inside tier two while Stryker's premium narrows.

The right way to read Apollo's bid is not as a JNJ exit story but as a market-structure event. Stryker's premium stopped being about scale and started being about the robotic surgery installed base—a flywheel that 3,000+ Mako systems, 50%+ global knee procedural penetration and the upcoming ASC-focused Mako RPS launch reinforce every quarter. Zimmer Biomet, Smith & Nephew and Globus Medical now trade at multiples that are essentially interchangeable with what Apollo will pay for DePuy, and that compression is unlikely to widen until the tier-two cluster consolidates. The contract manufacturers—Integer Holdings, the merged Tecomet/Orchid platform, and the additive-manufacturing specialists—are the structural winners as capital-constrained OEMs push more work outside their own four walls.